Wednesday 3 July 2024

The Pharma Letter Podcast — Episode 4 — The state of biotech investing

Biotechnology
Simon Wentworth
1 September 2021
podcast-episode4-1-

More on this story...

Pharmaceutical
Lightstone Ventures raises $375 million fund
14 September 2021
Pharmaceutical
Future of US pharmaceuticals: Examining the analysis of mergers
1 June 2022
Pharmaceutical
USA’s R&D tax credit bill moves forward
22 January 2024
Pharmaceutical
Life sciences industry optimism for 2024 and 2025 growth
8 May 2024


More ones to watch >


Today's issue

Pharmaceutical
Access to medicines key to British voters, survey shows
3 July 2024
Generics
US authorities clear Mylan in long-running antitrust probe
3 July 2024
Biotechnology
Touchlight and LeninBio announce link up
3 July 2024
Pharmaceutical
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Biotechnology
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Biotechnology
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
Biotechnology
First COPD nod could add billions to Dupixent revenue
3 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Touchlight and LeninBio announce link up
3 July 2024
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
First COPD nod could add billions to Dupixent revenue
3 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze